Kristi Rosa

iLLUMINATE trial meets primary endpoint of PFS in patients with previously untreated chronic lymphocytic leukemia compared with chlorambucil plus obinutuzumab.

Congress has voted to pass the Right to Try bill which will provide terminally ill patients with the ability to seek out experimental therapies not yet approved by the FDA.

An analysis of over 1,200 patients from pivotal studies finds that Esbriet helped blunt seasonal peaks in respiratory hospitalizations among patients with idiopathic pulmonary fibrosis.

At NORD’s 2018 Rare Impact Awards, Rare Disease Report® sat down with Estelle Benson, founder of GBS|CIDP Foundation International, to discuss what the organization is doing to fight GBS.

New data demonstrates clinical benefit in hemophilia B patients with pre-existing anti-AAV5 neutralizing antibodies.

The advisory committee did not feel there was substantial evidence regarding the safety and effectiveness of plazomicin for the treatment of bloodstream infections in patients with limited or no treatment options.

This is the first Breakthrough Therapy designation for a MenB vaccine to protect children as young as 1 year of age.

Misperceptions about the risk of HIV infection should be corrected at the time of testing, with PrEP initiated same-day, if appropriate.

International interdisciplinary collaboration studies can close the gap in the search for an HIV cure.